Venous thromboembolism in patients with acute leukemia, lymphoma, and multiple myeloma.

Research output: Contribution to journalArticlepeer-review

38 Scopus citations


The association of malignancies and venous thromboembolism (VTE) is a long held axiom in medicine. A growing number of studies have demonstrated that the risk of VTE associated with the hematological malignancies acute leukemia, lymphoma, and multiple myeloma is considerable. In fact, the incidence associated with these malignancies exceeds that for many solid tumors. Contributing factors include malignancy associated hypercoagulable factors; antineoplastic therapies such as high dose corticosteroids, L-asparaginase, and new immunomodulatory agents; central venous catheters; and hematopoietic growth factors. Primary and secondary pharmacological prophylaxis can be problematic in these patients who are often thrombocytopenic. Strategies to prevent VTE, especially upper extremity catheter-associated thrombosis need to be developed.

Original languageEnglish (US)
JournalThrombosis Research
Volume125 Suppl 2
StatePublished - Apr 2010

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Venous thromboembolism in patients with acute leukemia, lymphoma, and multiple myeloma.'. Together they form a unique fingerprint.

Cite this